These studies provide the basis for a potential modulation of resistance to IFN-α in renal cell carcinoma ex-vivo as well as in renal cell carcinoma patients receiving systemic IFN-α. Here, IFNA2 is linked to hereditary clear cell renal cell carcinoma.